ZNTL — Zentalis Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $290.44m
- -$198.54m
- 39
- 30
- 31
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.74 | ||
| Price to Tang. Book | 0.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -51.59% | ||
| Return on Equity | -51.86% | ||
| Operating Margin | -639.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 37 | 1.61 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Directors
- Anthony Sun CHM (49)
- Kevin Bunker CFD (49)
- Melissa Epperly CFO (43)
- Dimitris Voliotis SVP (57)
- Alexis Pinto SEC (54)
- David Johnson LED (55)
- Cam Gallagher DRC (51)
- Kimberly Blackwell IND (52)
- Enoch Kariuki IND (39)
- Karan Takhar IND (29)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 21st, 2017
- Public Since
- April 3rd, 2020
- No. of Shareholders
- 12
- No. of Employees
- 168
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 71,013,233
- Address
- 10275 Science Center Drive, Suite 200, SAN DIEGO, 92121
- Web
- https://www.zentalis.com/
- Phone
- +1 8582634333
- Contact
- Adam Levy
- Auditors
- Ernst & Young LLP
Upcoming Events for ZNTL
Q3 2024 Zentalis Pharmaceuticals Inc Earnings Release
Similar to ZNTL
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Zentalis Pharmaceuticals share price?
As of Today at 24:18 UTC, shares in Zentalis Pharmaceuticals are trading at $4.75. This share price information is delayed by 15 minutes.
How has the Zentalis Pharmaceuticals share price performed this year?
Shares in Zentalis Pharmaceuticals last closed at $4.75 and the price had moved by -83.62% over the past 365 days. In terms of relative price strength the Zentalis Pharmaceuticals share price has underperformed the S&P500 Index by -86.96% over the past year.
What are the analyst and broker recommendations for Zentalis Pharmaceuticals?
The overall consensus recommendation for Zentalis Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Zentalis Pharmaceuticals dividend yield?
Zentalis Pharmaceuticals does not currently pay a dividend.
Does Zentalis Pharmaceuticals pay a dividend?
Zentalis Pharmaceuticals does not currently pay a dividend.
When does Zentalis Pharmaceuticals next pay dividends?
Zentalis Pharmaceuticals does not currently pay a dividend.
How do I buy Zentalis Pharmaceuticals shares?
To buy shares in Zentalis Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zentalis Pharmaceuticals?
As of the previous close price of $4.75, shares in Zentalis Pharmaceuticals had a market capitalisation of $337.31m.
Where are Zentalis Pharmaceuticals shares listed?
Here are the trading details for Zentalis Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ZNTL
What kind of share is Zentalis Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Zentalis Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zentalis Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Zentalis Pharmaceuticals is $10.70. That is 125.26% above the last closing price of $4.75.
Analysts covering Zentalis Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.68 for the next financial year.
What is the trend in the Zentalis Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zentalis Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -71.2%.
As of the last closing price of $4.75, shares in Zentalis Pharmaceuticals were trading -66.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zentalis Pharmaceuticals PE Ratio?
The Zentalis Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals' management team is headed by:
- Anthony Sun - CHM
- Kevin Bunker - CFD
- Melissa Epperly - CFO
- Dimitris Voliotis - SVP
- Alexis Pinto - SEC
- David Johnson - LED
- Cam Gallagher - DRC
- Kimberly Blackwell - IND
- Enoch Kariuki - IND
- Karan Takhar - IND